EUCTR2010-019630-28-DE进行中（未招募）不适用
A RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL TO DETERMINE SAFETY AND EFFICACY OF ECULIZUMAB IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION (AMR) IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS REQUIRING DESENSITIZATION THERAPY
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female patients = 18 years old
- •- Patients with Stage IV or Stage V chronic kidney disease who will receive a kidney transplant from a living donor to whom they are sensitized and require desensitization prior to transplantation
- •- Patients must be willing and able to give written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 89
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •- Has received treatment with eculizumab at any time prior to enrolling in this study
- •- ABO incompatible with living donor
研究者
相似试验
进行中（未招募）
1 期
OPEN LABEL CONTROLLED TRIAL OF ECULIZUMAB IN THE PREVENTION OF AMR IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS REQUIRING DESENSITIZATIOAntibody mediated rejection after kidney transplantMedDRA version: 15.1Level: LLTClassification code 10064683Term: Antibody-mediated rejectionSystem Organ Class: 100000004870EUCTR2010-019630-28-SEAlexion Pharmaceuticals, Inc.80
进行中（未招募）
1 期
OPEN LABEL CONTROLLED TRIAL OF ECULIZUMAB IN THE PREVENTION OF AMR IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS REQUIRING DESENSITIZATIOEUCTR2010-019630-28-NLAlexion Pharmaceuticals, Inc.90
进行中（未招募）
1 期
OPEN LABEL CONTROLLED TRIAL OF ECULIZUMAB IN THE PREVENTION OF AMR IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS REQUIRING DESENSITIZATIOEUCTR2010-019630-28-GBAlexion Pharmaceuticals, Inc.102
进行中（未招募）
不适用
OPEN LABEL CONTROLLED TRIAL OF ECULIZUMAB IN THE PREVENTION OF AMR IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS REQUIRING DESENSITIZATIOAntiobdy mediated rejection after kidney transplantMedDRA version: 14.1Level: LLTClassification code 10064683Term: Antibody-mediated rejectionSystem Organ Class: 10021428 - Immune system disordersEUCTR2010-019630-28-ESAlexion Pharmaceuticals, Inc.80
进行中（未招募）
不适用
OPEN LABEL CONTROLLED TRIAL OF ECULIZUMAB IN THE PREVENTION OF AMR IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS REQUIRING DESENSITIZATIOEUCTR2010-019630-28-NOAlexion Pharmaceuticals, Inc.80